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Abstract
The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth
Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and
progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human
recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. The
vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF has
been evaluated so far in more than 1000 advanced NSCLC patients, as second line therapy. Two separate studies
were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of
immunogenicity, safety and preliminary efficacy in stage IIIb/IV NSCLC patients. In both clinical trials, patients
started vaccination 1 month after finishing first line chemotherapy. Vaccination at 4 sites with 2.4 mg of EGF (high
dose) was very safe. The most frequent adverse events were grade 1 or 2 injection site reactions, fever, headache
and vomiting. Patients had a trend toward higher antibody response. The percent of very good responders
significantly augmented and there was a faster decrease of circulating EGF. All vaccinated patients and those
classified as good responders immunized with high dose at 4 sites, had a large tendency to improved survival.
Introduction
In spite of an intensive research effort, lung cancer is the
leading cause of cancer death. For advanced non-small-cell
lung cancer (NSCLC), first-line platinum-based che-
motherapy has reached a plateau of effectiveness [1]. For
the second or third line therapy, the reported response rate
is usually less than 10% and the median survival time rarely
exceeds the 8 months boundary [2]. As a result, searching
for new efficacious drugs is warranted.
The Epidermal Growth Factor Receptor is a very well
validated target in NSCLC and it is over-expressed in a
very high percent of tumors classified as NSCLC [3]. Stra-
tegies to block this pathway include tyrosine kinase inhibi-
tors (TKIs) and monoclonal antibodies [2,3]. Erlotinib and
gefitinib, 2 small inhibitors, are recommended as second
or third line therapies, after the platinum doublet [4].
Moreover, gefitinib has recently been approved in Europe
and Japan as frontline treatment of patients bearing EGFR
activating mutations [5]. Cetuximab, a chimeric antibody
which recognizes the extracellular EGFR domain, can be
combined with first line cisplatin/vinorelbine in those sub-
jects with advanced or recurrent NSCLC [6].
Our team is using a different approach to target EGFR
consisting on a therapeutic vaccine (CimaVax-EGF) [7].
The vaccine is composed by human recombinant Epider-
mal Growth Factor (EGF) chemically conjugated to a car-
rier protein from Neisseria meningitides and emulsified in
Montanide ISA51. The vaccine is intended to induce anti-
bodies against EGF, one of the most important ligand of
the EGFR, that would block EGF-EGFR binding. So far, 6
clinical trials have been terminated, that proved that the
vaccine is safe and able to induce anti-EGF antibodies
together with a decrease of EGF concentration in sera
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ous process devoted to augment the specific immune
response. For self antigens, this response should overcome
the down-regulation that controls the natural autoimmu-
nity [15]. So far, the strategy to beat the natural tolerance
to the EGF has included 4 main directions: the refinement
of the adjuvant and carrier [8,9], and the systematic
exploration of the schedule and dose dependence
[10,13,14].
Previous studies have contributed to delineate CimaVax-
EGF components, P64k protein was chosen over Tetanus
Toxoid as the carrier molecule [8] and Montanide ISA 51
resulted in a more potent adjuvant as compared to Alum
[9,11]. The schedule-dependence of vaccination has been
evaluated and several schemes as well as combinations
with chemotherapy have been investigated [8-14].
In the randomized Phase II trial, 80 NSCLC subjects
received vaccination or best supportive care. Vaccination
consists of 0.6 mg of EGF, at 1 injection site. In the effi-
cacy analysis, there was a trend toward survival benefit for
all vaccinated patients that became significant in patients
younger than 60 years. The survival advantage was also
significant in subjects classified as good responders [anti
EGF titers ≥ 1: 4000 sera dilution] and in those in whom
the EGF concentration declined below 168 pg/ml [13].
Based in the previous evidences from the phase II study
and aiming to improve vaccine immunogenicity, a phase
III trial was designed with a higher antigen dose, adminis-
tered at multiple vaccination sites (2 deltoids & gluteus).
This Phase III clinical trial is currently ongoing and it is
primarily intended to evaluate the efficacy of CimaVax-
EGF vs. best supportive care in terms of survival. In this
manuscript, we make a comparison of the impact of using
high antigen dose distributed in 4 immunization sites
(Phase III trial) vs. low dose at 1 injection site (Phase II
trial) regarding safety, immunogenicity and preliminary
efficacy.
Materials and methods
Trial Design
For this analysis, the 40 all vaccinated patients from the
phase II clinical trial immunized at a single anatomic site
with the EGF vaccine [13] were compared to the first 40
vaccinated patients from a phase III clinical trial, which
received vaccination at multiple sites. These 40 patients
were evaluated as part of the first interim analysis of the
Phase III trial. Patients in both trials signed the informed
consent and both protocols were approved by the Institu-
tional Review Boards of the participating institutions.
Both clinical trials, enrolled patients older than 18 years
with histology or cytology proven NSCLC at stages IIIB
and IV and all patients have had measurable disease at
the moment of enrollment. Patients were required to
have an Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of 2 or less, adequate bone mar-
row reserve, white blood cells (WBC) count of at least 3,
000/μL, platelet count of at least 100, 000 μL, hemoglo-
b i no fa tl e a s t1 0g / d l ,l i f ee x p e c t a n c yo fa tl e a s t3
months, and creatinine, bilirubin, and transaminase levels
according to each institutional standard. Apart from the
Phase II trial, in the currently ongoing Phase III study,
patients were required to show at least stable disease to
first line chemotherapy. On the contrary, 26% of the
patients entered Phase II study with a progressive disease,
following 4 chemotherapy cycles.
Pregnancy or lactation, secondary malignancies, or
history of hypersensitivity to foreign proteins rendered
patients ineligible. All patients received 4 to 6 cycles of
platinum-based chemotherapy before random assign-
ment and finished first-line chemotherapy regimen at
least 4 weeks before entering trial.
Treatment Schedule
In both trials, a low-dose of cyclophosphamide (200 mg/
m
2), was administered by the intramuscular route, 3 days
before the first immunization with CimaVax-EGF (rEGF/
rp64k/Montanide ISA 51 VG). An induction phase of
4 quarterly immunizations and monthly re-immunizations
was performed. Immunized patients from the phase II
clinical trial received vaccination at a single anatomic site,
corresponding to 0.6 mg of EGF in 1.2 mL of water in oil
emulsion [13]. On the other hand, immunized patients
from the ongoing phase III trial, received vaccination at 4
sites (2 deltoids & 2 gluteus), equivalent to 2.4 mg of the
antigen, distributed in the 4 anatomic sites, corresponding
to 0.6 mg of EGF in 1.2 mL water in oil emulsion per site.
Patients assigned to the control arm in both protocols
received best supportive care.
Measurements of Antibody Titers
Blood samples were collected every 14 days for 60 days
and monthly thereafter. Anti-EGF antibody titers were
measured through an enzyme linked immunosorbent
assay (ELISA), as previously described [8]. Anti-EGF anti-
body titer was defined as the inverse of the highest serum
dilution with a final value of optical absorbance equal to
two times blank absorbance plus 3 times the SD. Response
is provided as the mean of antibodies titers (± S.E.M).
Patients were classified as good antibody responders
(GAR) if they reached anti-EGF antibody titers equal or
higher than 1:4, 000 sera dilution, and super good anti-
body responders (SGAR) if patients reached anti-EGF
antibody titers at least equivalent to 1:64, 000. An ELISA
test was used for the identification of EGF epitopes
recognized by sera of immunized patients and EGF
serum concentration was measured using a commercial
ELISA (Quantikine; R&D Systems Inc, Minneapolis, MN)
as previously described [10].
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A geometric T tests for independent samples was used to
compare the antibody titers for patients vaccinated under
the 2 different schemes. Pearson Chi square was used to
compare the demographic categorical variables as well as
the percentage of good and super-good responders. Pear-
son correlation coefficient and Spearman r correlation
were used to estimate the correlation between the immu-
nologic. Survival analysis was performed according to the
Kaplan-Meier method and the log rank estimate. All ana-
lyses were performed using SPSS for windows, version 16.
Results
Two separate studies were compared to assess the impact
of high dose vaccination at multiple anatomic sites in
terms of immunogenicity, safety and preliminary efficacy
of CimaVax-EGF in advanced NSCLC patients. In both
clinical trials, patients started vaccination 1 month after
finishing first line chemotherapy. In the Phase II study
(40 vaccinated patients), the vaccine dose was 0.6 mg of
the antigen, which was administered by the intramuscu-
lar route at 1 injection site. The Phase III trial is still
ongoing, but for the aim of comparability, we used the
data from the first 40 vaccinated patients. These subjects
r e c e i v e d4t i m e st h ep r e v i o u sd o s e( 2 . 4m go fE G F )t h a t
was administered by the intramuscular route at 4 ana-
tomic sites.
Before any analysis, patients recruited in the 2 trials were
compared in terms of demographic and tumor characteris-
tics. In general, vaccinated patients in both studies were
well balanced regarding the most important baseline fea-
tures (Table 1). All patients had an ECOG PS of 2 or less,
stage IIIB was the most represented and the non-adeno-
carcinoma subtype was the most frequent. Notably, there
were more patients younger than 60 years old in the phase
II study (low dose/1 injection site) as compared to the
Phase III trial (high dose/multiple injection sites).
Safety
In both studies, vaccination was very well tolerated. No
serious, related adverse events were reported in any of the
studies. In the Phase II study [13], the most frequent
adverse events consisted on grade 1 or 2 fever, headache,
asthenia, chills, tremors, injection site pain and vomiting.
On the other hand, the most frequent adverse events in
the Phase III were grade 1 or 2 injection site reactions,
fever, headache, vomiting, chills and nausea. No significant
differences were detected between the 2 vaccination
schemes in terms of the frequency or severity of the
adverse events.
Immune response
The humoral anti-EGF response was measured as the
principal surrogate marker of the immune response
elicited by vaccination. Patients vaccinated with low
dose at 1 site at the phase II study reached an anti-EGF
antibody titer of 1:3160 sera dilution (geometric mean),
while patients from the phase III study reached a anti-
EGF antibody titer of 1:7328 (geometric mean; T test
p > 0.05).
In addition, in both trials, patients were classified as
good antibody responders (GAR) or super good respon-
ders (SGAR). GAR and SGAR conditions had been repeat-
edly correlated with increased survival. Fifty-three percent
(52.8%) of the vaccinated patients in the phase II trial were
good responders and only 4 patients (10.8%) met the
SGAR condition. On the contrary, 56.4% of patients from
t h ev a c c i n ea r mi nt h eo n g o i n gp h a s eI I Is t u d ym e tt h e
GAR criterion while 30.8% were classified as super-
responders (SGAR). The percentage of SGAR was signifi-
cantly higher for patients vaccinated with the high dose, at
multiple sites (Table 2).
The EGF concentration in serum was also measured as a
marker of the vaccine activity. For both immunization
schemes, the anti-EGF antibody titer was inversely corre-
lated to the EGF serum concentration (spearman r correla-
tion, p < 0.05). However, the kinetic of the EGF reduction
was not the same. In the low dose/1 injection site trial,
EGF concentration reduction below a 500 pg/mL took
place after vaccinating patients for 10 months, while in the
Table 1 Demographic and tumors characteristics of
vaccinated patients by study
Demographic
Characteristics
Study
(Vaccine Arms)
Phase II Trial Phase III Trial
Age
Total 40 (100%) 40 (100%)
< 60 30 (75%) 25 (62.5%)
> 60 10 (25%) 15 (37.5%)
Race 34 (85%) 32 (80%)
White 34 (85%) 32 (80 %)
African Descendants 1 (2.5%) 6 (15%)
Other 5 (12.5%) 2 (5%)
Sex
F 10 (25%) 27 (31.8%)
M 30 (75%) 57 (68.2%)
Stage
IIIB 29 (72.5%) 56 (67.4%)
IV 11 (27.5%) 28 (32.6%)
Histological Type
ADC 12 (30.8%) 32 (38.6%)
No ADC 27 (67.5%) 52 (61.4%)
ECOG
0 9 (23%) 35 (40.4%)
1 24 (62%) 43 (50.6%)
2 6 (15%) 6 (7.9%)
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500 pg/ml threshold had effect after 76 days of vaccination
(Figure 1).
As previously reported [14], 46% of the patients showed
a predominant response against the B loop of EGF mole-
cule, using the single site vaccination approach. This
response was met between months 4 and 7 after starting
vaccination. Noticeably, at the same time points, 45.5% of
patients in the phase III trial, showed the same immuno-
dominant antibody profile. For both studies, the predomi-
nant subclasses were IgG3 and IgG4.
Preliminary efficacy
The median survival of the vaccinated patients in the
phase II trial was 6.47 months and the survival rate at 24
months was 27.27%. The median survival of the first 40
subjects from the phase III trial was 13.57 months and
the survival rate at 24 months was 34.2% (log rank
p value > 0.05).
Patients who achieved the GAR condition within the
Phase II study had a median survival of 11.76 months,
while GAR patients in the Phase III survived for 26.87
months (log rank p value > 0.05). Thirty-one percent of
patients in the Phase III were classified as SGAR and
had a median survival time of 29.9 months, while only 4
subjects in the Phase II achieved this condition, preclud-
ing any comparison within the SGAR cohort.
Discussion
The clinical evaluation of the EGF cancer vaccine started
15 years ago. So far, more than 1000 patients had been
immunized worldwide with encouraging results in the
treatment of advanced NSCLC and castration resistant
prostate cancer patients.
This vaccine is not intended to induce a cellular
response but a humoral immunity against EGF, a self pro-
tein. The antibodies elicited by vaccination provoke an
immune-castration of EGF, which hampers EGF-EGFR
interaction. Previous randomized clinical trials had identi-
fied the best carrier protein, adjuvant and vaccination
schedule. No randomized trials had been conducted so far
to assess the impact of immunizing at one vs. 4 anatomic
sites with low or high antigen dose. Here we compared 2
separate studies that target the same population (newly
diagnosed IIIb/IV NSCLC patients), that started vaccina-
tion 1 month after completing first line chemotherapy.
The most important distinction between the 2 populations
is the response to chemotherapy. All patients had at least
disease control in the Phase III, while 26% of subjects in
the phase II progressed after first line chemotherapy. Both
groups of vaccinated patients were well balanced regarding
the remaining important prognostic and predictive factors
for the vaccine efficacy. The percent of patients younger
than 60 was slightly higher in the Phase II as compared to
the Phase III trial. This is precisely the population that had
showed the greatest benefit after using CimaVax-EGF. A
better result of vaccination in younger people is antici-
pated, considering the physiologic aging of the immune
system, which results in the contraction of the naïve
repertoire.
In summary, vaccination at 4 sites with 2.4 mg of EGF
was safe and patients had a trend toward higher antibody
response and overall survival. The percentage of good
responders did not increase and the immune-dominance
Table 2 Patients’ classification according Immune response
Study Patients’ classification Anti EGF antibody titers
(Geometric mean of sera dilution)
GAR SGAR
Phase II Trial
(low dose, 1 injection site)
18 (52.8%) 4 (10.8%) 1:3160
Phase III trial
(high dose, 4 injection sites)
22 (56.4%) 12 (30.8%) 1:7328
Patients were classified as Good Antibody Responders (GAR) if they reached an anti-EGF antibody titer ≥ 1:4000 and SGAR if they reached an anti-EGF antibody
titer ≥ 1:64000.
 
Figure 1 Kinetic of Anti EGF antibodies and serum EGF
concentrations in the Phase III Trial (Vaccination with high
dose/4 anatomic sites). The anti-EGF antibody titer was inversely
correlated to the EGF serum concentration (spearman r correlation,
p < 0.05). in this high dose/multiple sites study the decay below
the 500 pg/mL threshold had effect after 76 days of vaccination.
Rodriguez et al. Journal of Immune Based Therapies and Vaccines 2011, 9:7
http://www.jibtherapies.com/content/9/1/7
Page 4 of 6profile was not modified. However, the percent of very
good responders significantly augmented and there was a
faster decrease of circulating EGF after vaccinating with
higher dose at multiple sites.
Previously, in mice, an EGF vaccine dose resulting
suboptimal when administered at a single site, induced a
robust immune response if fractionated in 2 or 4 limbs
[16]. Administering 4 times the dose at 4 anatomic sites
did not increase the immune response of mice.
In our clinical data set, we cannot determine which fac-
tor was more relevant for improving vaccine immunogeni-
city: the amount of antigen or the spatial distribution of
the antigen load. The distribution of vaccine inoculation
has been previously found to have a significant impact on
vaccine potency [17,18]. Theoretically, inoculating a vac-
cine at multiple sites would increase the total number of
precursors that are exposed to the antigen, thereby
increasing the number of activated specific effector cells.
However, this concept has not been systematically evalu-
ated in the clinical setting.
Conversely, increasing the dose has not always been cor-
related with greater antigenicity. Many clinical trials have
evaluated the impact of dose escalation and there was
found to be no direct relationship between dose and
immune response [19-21]. Still, reduction of antigen
below a minimal threshold can bring the response to a
halt and in contrast, persistence of the antigen may stop
the immune response through the deletion of effector cells
[22]. As a corollary, the optimal dose should be established
for each vaccine in the clinical setting.
Even though we have preliminary evidences of improved
immunogenicity and clinical benefit of the new vaccina-
tion approach, the definitive information will come out
after closing enrolment and follow-up of the patients in
the ongoing Phase III trial.
Nonetheless, we still have many pending questions: can
the immune response be augmented or have we reached a
plateau? Could we have the same effect by vaccinating
with low dose at multiple sites? Would we induce clonal
exhaustion after repeatedly vaccinating with a high dose?
Which other manipulations can be done to improve
immunogenicity (vaccination in lymphopenia, distinct
prime and boosting? So far, a parallel trial evaluating a
vaccine-chemotherapy-vaccine schedule is ongoing. The
rationale behind is to expand the immune precursors
before chemotherapy, to facilitate their preferential
homeostatic recovery by re-immunizing after the cytotoxic
regimen.
In summary, the evidence of higher immunogenicity
and clinical benefit of the new vaccination dose and
method is consolidating; the next step would be to con-
firm if all vaccinated patients had a significantly better
survival as compared to controls. The final result of this
trial is eagerly awaited.
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